Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Up 40.1% in June

Evoke Pharma, Inc. (NASDAQ:EVOK) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 24,800 shares, a growth of 40.1% from the May 31st total of 17,700 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 27,900 shares, the short-interest ratio is currently 0.9 days.

Evoke Pharma Price Performance

NASDAQ:EVOK traded down $0.06 during mid-day trading on Monday, reaching $0.47. The company’s stock had a trading volume of 23,794 shares, compared to its average volume of 45,337. The stock has a market cap of $4.06 million, a P/E ratio of -0.26 and a beta of 0.38. The company’s fifty day simple moving average is $0.49 and its two-hundred day simple moving average is $0.65. Evoke Pharma has a twelve month low of $0.40 and a twelve month high of $1.77.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%. The company had revenue of $1.74 million during the quarter.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Evoke Pharma in a research note on Saturday. They issued a “sell” rating for the company.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.